Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Ref Type||Journal Article|
|Authors||Hancock BM, McGuire KL, Tsuji S, Reil K, Hernandez V, Giacalone MJ, Godbey WT|
|Title||A Single Intravesical Instillation of VAX014 Inhibits Orthotopic Superficial Bladder Tumor Implantation to Increase Survival.|
|Abstract Text||VAX014 minicells (VAX014) have been previously characterized as an integrin-specific oncolytic biotherapeutic agent. The present study was designed to evaluate the potential of VAX014 as an immediate post-operative intravesical adjuvant therapy in the treatment of non-muscle invasive bladder cancer (NMIBC).The ability of VAX014 to kill a panel of dissociated urothelial carcinoma cell lines was tested in vitro. In vivo experiments were conducted using a single intravesical dose of VAX014 in the anti-implantation variation of the MB49 syngeneic orthotopic bladder cancer model with tumor implantation and overall survival rates serving as study endpoints.VAX014 rapidly killed dissociated urothelial carcinoma cells, while single dose in vivo pharmacology studies demonstrated the dose-dependent ability of VAX014 to prevent tumor implantation and development, ultimately resulting in a significant survival advantage compared to controls.These results suggest that VAX014 holds potential as an immediate post-operative adjuvant therapy in NMIBC.|
|Molecular Profile||Treatment Approach|
|Gene Name||Source||Synonyms||Protein Domains||Gene Description||Gene Role|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|VAX014||VAX-IP|VAX 014|VAX-014||VAX014 is bacterial minicell therapeutic comprising E. coli engineered to express Invasin and the bacterial toxin perfringolysin O (PFO), which delivers the toxin to tumor cells expressing Integrin alpha3beta1 or alpha5beta1, potentially resulting in increased tumor cell apoptosis and decreased tumor growth (PMID: 27919942, PMID: 27119118).|
|Gene||Variant||Impact||Protein Effect||Variant Description||Associated with drug Resistance|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||bladder urothelial carcinoma||not applicable||VAX014||Preclinical||Actionable||In a preclinical study, VAX014 induced cell-killing in dissociated mouse and human urothelial carcinoma cell lines in culture, and inhibited tumor growth and improved survival in a syngeneic bladder cancer model (PMID: 27919942).||27919942|